Company Filing History:
Years Active: 2025
Title: Mark Frattini: Innovator in Leukemia Treatment
Introduction
Mark Frattini is a notable inventor based in Ridgewood, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of leukemia and myelodysplastic syndrome. His innovative approach combines existing therapies to enhance patient outcomes.
Latest Patents
Frattini holds a patent for "Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome." This patent outlines methods for using 5-azacytidine in conjunction with additional agents to treat diseases and disorders, including acute myeloid leukemia (AML). His work is pivotal in advancing treatment options for patients suffering from these serious conditions.
Career Highlights
Mark Frattini is associated with Celgene Quanticel Research, Inc., where he continues to push the boundaries of cancer research. His dedication to improving therapeutic strategies has positioned him as a key figure in the medical research community.
Collaborations
Throughout his career, Frattini has collaborated with esteemed colleagues, including C L Beach and Shelonitda Rose. These partnerships have fostered a collaborative environment that enhances the development of innovative treatment methods.
Conclusion
Mark Frattini's contributions to leukemia treatment through his patent and collaborative efforts exemplify the impact of innovation in medicine. His work continues to inspire advancements in cancer therapies, ultimately benefiting patients in need.